头孢哌酮-舒巴坦钠治疗社区获得性肺炎105例临床观察

Clinical observation of cefoperazone sodium and sulbactam sodium in treatment of 105 patients with community acquired pneumonia

目的 探讨头孢哌酮.舒巴坦钠治疗社区获得性肺炎的临床疗效和安全性.方法 将210例社区获得性肺炎患者随机分为治疗组和对照组,每组各105例,治疗组采用头孢哌酮-舒巴坦钠治疗,对照组接受头孢唑啉治疗,疗程均为7 d.观察两组患者的临床疗效和不良反应.结果 治疗组总有效率为90.48%,对照组总有效率为80.00%,两组临床疗效差异有统计学意义（P〈0.05） 对照组和治疗组分别有3例和2例发生不良发应,停药后不良反应均消失,治疗组与对照组的不良反应发生率差异无统计学意义（P〉0.05）.结论 头孢哌酮-舒巴坦钠治疗社区获得性肺炎,可明显的提高临床疗效,缩短病程,具有良好的临床效果.

Objective To study the efficacy and safety of cefoperazone sodium and sulbactam sodium in treatment of patients with community acquired pneumonia.Methods 210 patients with community acquired pneumonia were randomly divided into two groups 105 cases in treatment group （the patients were treated with cefoperazone sodium and sulbactam sodium）, 105 cases in control group（the patients were treated with cefazolin）.Both groups were treated for 7 days efficacy and safety of both groups were evaluated.Results The total effective rate was 90.48% in the treatment group and 80.00% in the control group,there were significant differences between the two groups in treatment effect rate （P 〈0.05）.There are 3 and 2 cases in the control group and treatment group respectively has adverse effect,and there were no significant differences between the two groups＇ adverse effect（P〉0.05）.Conclusion Cefoperazone sodium and sulbactam sodium in treatment of community acquired pneumonia could obviously improve therapeutic efficacy,shorten the disease＇s develop course,and had a good clinical prospect.